Sang Chul Lee1, Keun Suk Park1, Jee Youn Moon2, Eun Jung Kim1, Yong-Chul Kim1, Hyejin Seo1, Joon Kyung Sung1, Da Jeong Lee3. 1. Department of Anesthesiology and Pain Medicine, Seoul National University Hospital College of Medicine, Seoul, Republic of Korea. 2. Department of Anesthesiology and Pain Medicine, Seoul National University Hospital College of Medicine, Seoul, Republic of Korea. Electronic address: jymoon0901@gmail.com. 3. University Medical Center, De La Salle Health Sciences Institute, Dasmariñas, Cavite, Philippines.
Abstract
PURPOSE: Calmare therapy (CT) has been suggested as a novel treatment for managing chronic pain. Recently, it was reported to show a positive therapeutic outcome for managing neuropathic pain condition. We performed an exploratory prospective study on the effectiveness of CT in patients with various types of cancer-related neuropathic pain (CNP). METHOD: We performed an open-labeled, single-arm, exploratory study on the effectiveness of CT in patients with various types of cancer-related neuropathic pain (CNP). The primary endpoint was a comparison of the 11-point Numerical Rating Scale (NRS) pain score at one month with the baseline score in each patient. Brief Pain Inventory (BPI) and consumption of opioid were also evaluated during follow-up period. RESULTS: CT significantly decreased NRS pain score at one month from baseline (p < 0.001) in 20 patients with chemotherapy-induced peripheral neuropathy (n = 6), metastatic bone pain (n = 7), and post-surgical neuropathic pain (n = 7). It also improved overall BPI scores, decreased consumption of rescue opioid (p = 0.050), and was found satisfactory by a half of patients (n = 10, 50.0%). CONCLUSIONS: Our preliminary results suggest that CT may be considered for cancer patients with various types of CNP. Large studies are necessary to confirm our findings and ascertain which additional CNP show positive response to CT.
PURPOSE: Calmare therapy (CT) has been suggested as a novel treatment for managing chronic pain. Recently, it was reported to show a positive therapeutic outcome for managing neuropathic pain condition. We performed an exploratory prospective study on the effectiveness of CT in patients with various types of cancer-related neuropathic pain (CNP). METHOD: We performed an open-labeled, single-arm, exploratory study on the effectiveness of CT in patients with various types of cancer-related neuropathic pain (CNP). The primary endpoint was a comparison of the 11-point Numerical Rating Scale (NRS) pain score at one month with the baseline score in each patient. Brief Pain Inventory (BPI) and consumption of opioid were also evaluated during follow-up period. RESULTS:CT significantly decreased NRS pain score at one month from baseline (p < 0.001) in 20 patients with chemotherapy-induced peripheral neuropathy (n = 6), metastatic bone pain (n = 7), and post-surgical neuropathic pain (n = 7). It also improved overall BPI scores, decreased consumption of rescue opioid (p = 0.050), and was found satisfactory by a half of patients (n = 10, 50.0%). CONCLUSIONS: Our preliminary results suggest that CT may be considered for cancerpatients with various types of CNP. Large studies are necessary to confirm our findings and ascertain which additional CNP show positive response to CT.
Authors: Christine Miaskowski; Judy Mastick; Steven M Paul; Kimberly Topp; Betty Smoot; Gary Abrams; Lee-May Chen; Kord M Kober; Yvette P Conley; Margaret Chesney; Kay Bolla; Grace Mausisa; Melissa Mazor; Melisa Wong; Mark Schumacher; Jon D Levine Journal: J Pain Symptom Manage Date: 2017-01-04 Impact factor: 3.612
Authors: Charles Loprinzi; Jennifer G Le-Rademacher; Neil Majithia; Ryan P McMurray; Carrie R O'Neill; Markus A Bendel; Andreas Beutler; Daniel H Lachance; Andrea Cheville; David M Strick; David F Black; Jon C Tilburt; Thomas J Smith Journal: Support Care Cancer Date: 2019-06-17 Impact factor: 3.603
Authors: Neil Majithia; Thomas J Smith; Patrick J Coyne; Salahadin Abdi; Deirdre R Pachman; Daniel Lachance; Randy Shelerud; Andrea Cheville; Jeffrey R Basford; David Farley; Carrie O'Neill; Kathryn J Ruddy; Frank Sparadeo; Andreas Beutler; Charles L Loprinzi Journal: Support Care Cancer Date: 2016-04-04 Impact factor: 3.603